Previous 10 | Next 10 |
Vericel press release ( NASDAQ: VCEL ): Q3 GAAP EPS of -$0.14 misses by $0.04 . Revenue of $38.6M (+11.9% Y/Y) misses by $1.3M . MACI ® net revenue of $31.0 million, Epicel ® net revenue of $7.3 million, and NexoBrid ® revenue of $0.2...
Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the spo...
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel...
Summary MACI is a great product, but even generous peak sales assumptions don’t justify making this a buy. Even if NexoBrid is approved and matches Epicel revenues, it does not change my valuation much. The stock has fallen quite a bit since hitting $60+/share, but it...
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Confe...
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor confe...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note : John and Wade here – today, we have a special guest issue from InvestorPlace’s own Luke Lango. The markets have slid following the Fed symposium in Jackson Hole over the weekend, and a ...
Image source: The Motley Fool. Vericel (NASDAQ: VCEL) Q2 2022 Earnings Call Aug 03, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Vericel (VCEL) Q2 2022 Earnings Call Transcript
Vericel Corporation (VCEL) Q2 2022 Earnings Conference Call August 03, 2022 08:30 AM ET Company Participants Eric Burns - Head of Financial Planning and Analysis & Investor Relations Nick Colangelo - President & Chief Executive Officer Joe Mara - Chief Fi...
The following slide deck was published by Vericel Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Vericel Corporation 2022 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, w...
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s m...
2024-07-08 00:00:04 ET Ryan Zimmerman from BTIG issued a price target of $56.00 for VCEL on 2024-07-05 10:09:00. The adjusted price target was set to $56.00. At the time of the announcement, VCEL was trading at $46.68. The overall price target consensus is at $48.00 with...